Biocon Ltd reported a mixed set of Q4 FY26 results, where underlying resilience in its biosimilars portfolio cushioned the impact of a steep profit decline driven largely by a high base effect and one-off items from the previous year. The company posted a consolidated net profit of ₹126 crore, down 63.5% year-on-year from ₹345 crore […]